The Rhythm | Issue 23
Issue 23 | Week of 7th September 2026
ESC Congress 2026 concluded in Munich on 31 August. This issue covers papers first published on 30 and 31 August, plus CARDIO-TTRansform, first published on 28 August and held over from last issue by editorial choice.
Cardiology Intelligence Briefing: what a result actually proves
Every paper this week raised a version of the same question: a result can look like progress, but how much does it actually prove? In pulmonary embolism, a catheter-based intervention filled a specific, long-standing evidence gap, sharply cutting early deterioration when added to standard anticoagulation, though the trial was too small to show it saves lives outright.1 In severe tricuspid regurgitation, a randomised comparison against medical therapy alone gave a previously undertreated, high-risk population its first clear evidence that intervention reduces death or hospitalisation, not just symptoms.2 Where the sequence of two established procedures was in question, new evidence offered a genuine choice between two reasonable strategies rather than replacing one with a better one.3
Two papers went further and tested the assumptions behind existing practice. A sham-controlled ablation trial found that a treatment already recommended in guidelines reduces atrial fibrillation (AF) burden on structured monitoring, but could not show that clinically noticed recurrence or quality of life improve more than a convincing sham delivers on its own.4 A gene-silencing therapy with a clear, measurable biological effect on its target protein, meanwhile, still failed to translate that effect into fewer cardiovascular events across the trial population as a whole, its benefit surviving only in a subgroup analysis not yet tested independently.5
Taken together, the week is a reminder that a positive result answers only the question it was designed to ask. A reduction in deterioration is not a proven survival benefit. Two strategies performing equally is not evidence that either is superior. A procedure that beats a sham on rhythm has not beaten it on how the patient feels. A drug that lowers its target protein has not lowered cardiovascular risk on its own. This week rewards reading past the headline to the specific question each trial actually answered.
